论文部分内容阅读
近数十年来,肿瘤药物治疗有了比较迅速的发展,但肿瘤化疗目前尚有选择性差、全身毒性反应重。易于产主耐药性和缓解期短的缺点.因此临床使用治疗腹腔恶性肿瘤疗效受到一定的限制.70年代初即有作者探索经腹腔内化疗的途径.当时治疗的主要目的为控制腹水.此后Chabner等发现腹膜对抗癌药物有弥散屏障(dif-fusion barrier)的作用,提示抗癌药物有可能在腹腔内高浓度集聚,从而增加药物的杀细胞效应,提高疗效.最近这一领域的研究已从基础转向临床,结果表明腹腔化疗特别是顺铂“双途径”化疗安全、有效、是一种有希望的给药途径.
In recent decades, there has been relatively rapid development of oncological drug treatment. However, tumor chemotherapy has poor selectivity and systemic toxicity. Easy to produce drug resistance and short remission shortcomings. Therefore, the clinical use of treatment of abdominal malignant tumors is limited. The early 70s, the authors explore the path of intraperitoneal chemotherapy. At that time the main purpose of treatment was to control ascites. Chabner et al. found that the peritoneal anticancer drug has a dif-fusion barrier, suggesting that anticancer drugs may be concentrated in the abdominal cavity at high concentrations, thereby increasing the cytotoxicity of the drug and improving the efficacy. Recent studies in this area Has changed from basic to clinical, the results show that intraperitoneal chemotherapy, especially cisplatin “two-way” chemotherapy is safe, effective, is a promising route of administration.